Cargando…

New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review

BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhumaid, Saad, Al Mutair, Abbas, Rabaan, Ali A., ALShakhs, Fatemah M., Choudhary, Om Prakash, Yong, Shin Jie, Nainu, Firzan, Khan, Amjad, Muhammad, Javed, Alhelal, Fadil, Al Khamees, Mohammed Hussain, Alsouaib, Hussain Ahmed, Al Majhad, Ahmed Salman, AL-Tarfi, Hassan Redha, ALyasin, Ali Hussain, Alatiyyah, Yaqoub Yousef, Alsultan, Ali Ahmed, Alessa, Mohammed Essa, Alessa, Mustafa Essa, Alissa, Mohammed Ahmed, Alsayegh, Emad Hassan, Alshakhs, Hassan N., Al Samaeel, Haidar Abdullah, AlShayeb, Rugayah Ahmed, Alnami, Dalal Ahmed, Alhassan, Hussain Ali, Alabdullah, Abdulaziz Abdullah, Alhmed, Ayat Hussain, AlDera, Faisal Hussain, Hajissa, Khalid, Al-Tawfiq, Jaffar A., Al-Omari, Awad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559550/
https://www.ncbi.nlm.nih.gov/pubmed/36229799
http://dx.doi.org/10.1186/s12876-022-02507-3
_version_ 1784807662795358208
author Alhumaid, Saad
Al Mutair, Abbas
Rabaan, Ali A.
ALShakhs, Fatemah M.
Choudhary, Om Prakash
Yong, Shin Jie
Nainu, Firzan
Khan, Amjad
Muhammad, Javed
Alhelal, Fadil
Al Khamees, Mohammed Hussain
Alsouaib, Hussain Ahmed
Al Majhad, Ahmed Salman
AL-Tarfi, Hassan Redha
ALyasin, Ali Hussain
Alatiyyah, Yaqoub Yousef
Alsultan, Ali Ahmed
Alessa, Mohammed Essa
Alessa, Mustafa Essa
Alissa, Mohammed Ahmed
Alsayegh, Emad Hassan
Alshakhs, Hassan N.
Al Samaeel, Haidar Abdullah
AlShayeb, Rugayah Ahmed
Alnami, Dalal Ahmed
Alhassan, Hussain Ali
Alabdullah, Abdulaziz Abdullah
Alhmed, Ayat Hussain
AlDera, Faisal Hussain
Hajissa, Khalid
Al-Tawfiq, Jaffar A.
Al-Omari, Awad
author_facet Alhumaid, Saad
Al Mutair, Abbas
Rabaan, Ali A.
ALShakhs, Fatemah M.
Choudhary, Om Prakash
Yong, Shin Jie
Nainu, Firzan
Khan, Amjad
Muhammad, Javed
Alhelal, Fadil
Al Khamees, Mohammed Hussain
Alsouaib, Hussain Ahmed
Al Majhad, Ahmed Salman
AL-Tarfi, Hassan Redha
ALyasin, Ali Hussain
Alatiyyah, Yaqoub Yousef
Alsultan, Ali Ahmed
Alessa, Mohammed Essa
Alessa, Mustafa Essa
Alissa, Mohammed Ahmed
Alsayegh, Emad Hassan
Alshakhs, Hassan N.
Al Samaeel, Haidar Abdullah
AlShayeb, Rugayah Ahmed
Alnami, Dalal Ahmed
Alhassan, Hussain Ali
Alabdullah, Abdulaziz Abdullah
Alhmed, Ayat Hussain
AlDera, Faisal Hussain
Hajissa, Khalid
Al-Tawfiq, Jaffar A.
Al-Omari, Awad
author_sort Alhumaid, Saad
collection PubMed
description BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. METHODS: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. RESULTS: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. CONCLUSION: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks.
format Online
Article
Text
id pubmed-9559550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95595502022-10-14 New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review Alhumaid, Saad Al Mutair, Abbas Rabaan, Ali A. ALShakhs, Fatemah M. Choudhary, Om Prakash Yong, Shin Jie Nainu, Firzan Khan, Amjad Muhammad, Javed Alhelal, Fadil Al Khamees, Mohammed Hussain Alsouaib, Hussain Ahmed Al Majhad, Ahmed Salman AL-Tarfi, Hassan Redha ALyasin, Ali Hussain Alatiyyah, Yaqoub Yousef Alsultan, Ali Ahmed Alessa, Mohammed Essa Alessa, Mustafa Essa Alissa, Mohammed Ahmed Alsayegh, Emad Hassan Alshakhs, Hassan N. Al Samaeel, Haidar Abdullah AlShayeb, Rugayah Ahmed Alnami, Dalal Ahmed Alhassan, Hussain Ali Alabdullah, Abdulaziz Abdullah Alhmed, Ayat Hussain AlDera, Faisal Hussain Hajissa, Khalid Al-Tawfiq, Jaffar A. Al-Omari, Awad BMC Gastroenterol Research BACKGROUND: Liver diseases post-COVID-19 vaccination is extremely rare but can occur. A growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liver enzymes and liver injuries, etc., may be potential consequence of COVID-19 vaccines. OBJECTIVES: To describe the results of a systematic review for new-onset and relapsed liver disease following COVID-19 vaccination. METHODS: For this systematic review, we searched Proquest, Medline, Embase, PubMed, CINAHL, Wiley online library, Scopus and Nature through the Preferred Reporting Items for Systematic Reviews and Meta Analyses PRISMA guideline for studies on the incidence of new onset or relapsed liver diseases post-COVID-19 vaccination, published from December 1, 2020 to July 31, 2022, with English language restriction. RESULTS: Two hundred seventy-five cases from one hundred and eighteen articles were included in the qualitative synthesis of this systematic review. Autoimmune hepatitis (138 cases) was the most frequent pathology observed post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes (26 cases) and liver injury (21 cases). Other cases include splanchnic vein thrombosis, acute cellular rejection of the liver, jaundice, hepatomegaly, acute hepatic failure and hepatic porphyria. Mortality was reported in any of the included cases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein thrombosis (n = 6, 42.8%), jaundice (n = 1, 12.5%), raised liver enzymes (n = 2, 7.7%), and autoimmune hepatitis (n = 3, 2.2%). Most patients were easily treated without any serious complications, recovered and did not require long-term hepatic therapy. CONCLUSION: Reported evidence of liver diseases post-COIVD-19 vaccination should not discourage vaccination against this worldwide pandemic. The number of reported cases is relatively very small in relation to the hundreds of millions of vaccinations that have occurred and the protective benefits offered by COVID-19 vaccination far outweigh the risks. BioMed Central 2022-10-13 /pmc/articles/PMC9559550/ /pubmed/36229799 http://dx.doi.org/10.1186/s12876-022-02507-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Alhumaid, Saad
Al Mutair, Abbas
Rabaan, Ali A.
ALShakhs, Fatemah M.
Choudhary, Om Prakash
Yong, Shin Jie
Nainu, Firzan
Khan, Amjad
Muhammad, Javed
Alhelal, Fadil
Al Khamees, Mohammed Hussain
Alsouaib, Hussain Ahmed
Al Majhad, Ahmed Salman
AL-Tarfi, Hassan Redha
ALyasin, Ali Hussain
Alatiyyah, Yaqoub Yousef
Alsultan, Ali Ahmed
Alessa, Mohammed Essa
Alessa, Mustafa Essa
Alissa, Mohammed Ahmed
Alsayegh, Emad Hassan
Alshakhs, Hassan N.
Al Samaeel, Haidar Abdullah
AlShayeb, Rugayah Ahmed
Alnami, Dalal Ahmed
Alhassan, Hussain Ali
Alabdullah, Abdulaziz Abdullah
Alhmed, Ayat Hussain
AlDera, Faisal Hussain
Hajissa, Khalid
Al-Tawfiq, Jaffar A.
Al-Omari, Awad
New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title_full New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title_fullStr New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title_full_unstemmed New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title_short New-onset and relapsed liver diseases following COVID-19 vaccination: a systematic review
title_sort new-onset and relapsed liver diseases following covid-19 vaccination: a systematic review
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559550/
https://www.ncbi.nlm.nih.gov/pubmed/36229799
http://dx.doi.org/10.1186/s12876-022-02507-3
work_keys_str_mv AT alhumaidsaad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT almutairabbas newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT rabaanalia newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alshakhsfatemahm newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT choudharyomprakash newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT yongshinjie newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT nainufirzan newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT khanamjad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT muhammadjaved newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alhelalfadil newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alkhameesmohammedhussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alsouaibhussainahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT almajhadahmedsalman newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT altarfihassanredha newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alyasinalihussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alatiyyahyaqoubyousef newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alsultanaliahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alessamohammedessa newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alessamustafaessa newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alissamohammedahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alsayeghemadhassan newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alshakhshassann newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alsamaeelhaidarabdullah newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alshayebrugayahahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alnamidalalahmed newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alhassanhussainali newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alabdullahabdulazizabdullah newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alhmedayathussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alderafaisalhussain newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT hajissakhalid newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT altawfiqjaffara newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview
AT alomariawad newonsetandrelapsedliverdiseasesfollowingcovid19vaccinationasystematicreview